Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Alkermes initiated a Phase 2 proof-of-concept study of ALKS 7290, an oral orexin 2 receptor agonist, as an adjunctive therapy to antidepressants in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial will enroll approximately 180 participants for six weeks of treatment, with safety as the primary objective and MADRS/CGI-S symptom improvement as secondary endpoints.
Key figures
- Drug Name
- ALKS 7290
- Phase Of Trial
- Phase 2
- Planned enrollment
- 180
- Trial registration
- NCT07901179
- Trial duration weeks
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.